List of All Articles with Tag ''

STL Cardinals rumors: How would Mike Trout fit on this team? Jack Flaherty continues to struggle in Baltimore. Why Shohei Ohtani is an unlikely move.

PointsBet is giving new users a $150 credit for any NFL jersey at Fanatics! See here how to sign up and claim this limited-time guaranteed offer.

Joining a list of musicians including John Lydon, Ed Sheeran and Nick Cave who have slammed the tech, Brian May has said he finds the use of AI in music “massively scary” as he believes it possesses the power to cause “evil”.

French prosecutors have opened an investigation following the incident in Bordeaux at the weekend.

A famed Russian conductor allowed climate protesters who disrupted a performance at a classical music festival in Switzerland to address the crowd, despite grumbling from some members of the audience.

The British scientist who led the team that cloned Dolly the Sheep in 1996 has died at age 79

Elon Musk has denied reports that his brain implant startup Neuralink killed monkeys during research experiments, claiming instead that tests were only done on “terminal” primates. Neuralink admitted to euthanizing eight animals during trials of its brain-computer interface technology last year, however denied accusations from the Physicians Committee for Responsible Medicine (PCRM) that it subjected monkeys to “extreme suffering”. The animal rights group accused Neuralink of “inadequate animal care” at the company’s lab at the University of California’s Davis Primate Centre, alleging that nine violations of the Animal Welfare Act were committed. Neuralink defended its animal testing record in a blog post last year, claiming that it is “absolutely committed to working with animals in the most humane and ethical way possible”. The firm also noted that “all novel medical devices and treatments” must be tested on animals before they can be trialled on humans. “The use of every animal was extensively planned and considered to balance scientific discovery with the ethical use of animals,” the blog post stated. Neuralink CEO Elon Musk has now added more details about the startup’s animal testing practices, after the issue was brought up by one of his followers on X, formerly known as Twitter. “No monkey has died as a result of a Neuralink implant,” Mr Elon Musk posted to X. “First our early implants, to minimise risk to healthy monkeys, we chose terminal monkeys (close to death already).” Mr Musk founded Neuralink in 2016 with the ultimate aim of merging artificial intelligence with the human brain. An implanted chip could improve hearing and vision, while also delivering “enhanced abilities” like greater reasoning and anxiety relief, according to the tech billionaire. Early applications of the technology will be for treating brain disorders and neurological conditions, though the company is yet to set a date for when its chips will be ready to use. In May, Neuralink revealed that it had received approval from the US Food and Drug Administration (FDA) to begin testing its technology on humans. Neuralink said that FDA approval “represents an important first step that will one day allow our technology to help many people”. Read More 10 ways AI will change the world – from curing cancer to wiping out humanity SpaceX launch of Starship rocket on hold amid ‘mishap investigation’ Famed tech journalist deletes X account with epic rant at Elon Musk First photo emerges of Elon Musk and his baby twins with Neuralink director

Hurricane Lee is whipping up waves of more than 15 feet as the Category 3 storm cranks through open waters just north of the Caribbean region

By David Morgan WASHINGTON The U.S. House of Representatives returns this week for an expected political brawl over

Scotland are closing in on qualification for next year's European Championship, but manager Steve Clarke believes facing England in a friendly on Tuesday will give a true reflection of...

By Oliver Griffin BOGOTA Colombia's government is considering revising rules to make majority state-run energy company Ecopetrol an

KENNESAW, Ga.--(BUSINESS WIRE)--Sep 11, 2023--